Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

ABSTRACT:

Background

Nevirapine-based antiretroviral therapy is the predominant (and often the only) regimen available for children in resource-limited settings. Nevirapine resistance after exposure to the drug for prevention of maternal-to-child human immunodeficiency virus (HIV) transmission is common, a problem that has led to the recommendation of ritonavir-boosted lopinavir in such settings. Regardless of whether there has been prior exposure to nevirapine, the performance of nevirapine versus ritonavir-boosted lopinavir in young children has not been rigorously established.

Methods

In a randomized trial conducted in six African countries and India, we compared the initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine or ritonavir-boosted lopinavir in HIV

SUBMITTER: Violari A 

PROVIDER: S-EPMC3443859 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature